BioDelivery Sciences International (BDSI) was Reiterated by FBR Capital to “Outperform” while Lowering the Price Target of the company shares to $ 9 from a previous price target of $12 . FBR Capital advised their investors in a research report released on May 4, 2016.
Many Wall Street Analysts have commented on BioDelivery Sciences International. Shares were Reiterated by Laidlaw on Mar 14, 2016 to “Buy” and Lowered the Price Target to $ 11 from a previous price target of $17 .Shares were Reiterated by FBR Capital on Mar 11, 2016 to “Outperform” and Lowered the Price Target to $ 12 from a previous price target of $13 .BioDelivery Sciences International was Initiated by Piper Jaffray to “Overweight” on Feb 8, 2016.
On the company’s financial health, BioDelivery Sciences International reported $0.19 EPS for the quarter, missing the analyst consensus estimate by $ -0.37 based on the information available during the earnings call on Mar 10, 2016. Analyst had a consensus of $0.56. The company had revenue of $32.20 million for the quarter, compared to analysts expectations of $52.40 million.
BioDelivery Sciences International closed down -0.27 points or -7.99% at $3.11 with 13,93,943 shares getting traded on Monday. Post opening the session at $3.38, the shares hit an intraday low of $3 and an intraday high of $3.38 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Mar 23, 2016, Charles Bramlage (director) purchased 8,850 shares at $2.82 per share price. According to the SEC, on Mar 22, 2016, Niraj Vasisht (Chief Technology Officer) purchased 1,000 shares at $2.80 per share price. On Mar 22, 2016, Barry I Feinberg (director) purchased 10,000 shares at $2.74 per share price, according to the Form-4 filing with the securities and exchange commission.
BioDelivery Sciences International Inc. is a specialty pharmaceutical company. The Company develops and commercializes either on its own or in partnerships with third parties applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology a small erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product ONSOLIS (fentanyl buccal soluble film) as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate BELBUCA utilize its BEMA technology.